Literature DB >> 17390048

Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma.

Shang-Bin Yang1, Xiao-Bo Zhou, Hong-Xia Zhu, Lan-Ping Quan, Jin-Feng Bai, Jie He, Yan-Ning Gao, Shu-Jun Cheng, Ning-Zhi Xu.   

Abstract

Aurora-A/BTAK/STK15 gene which encodes a centrosome-associated kinase is located on chromosome 20q13.2, a highly amplified region in various human tumors. Recent studies have demonstrated the overexpression and amplification of Aurora-A in many malignant human cancers. The purpose of this study was to investigate the amplification and expression of Aurora-A in esophageal squamous cell carcinoma. Amplification of Aurora-A was determined by fluorescence in situ hybridization in 7 esophageal cancer cell lines and real-time PCR in 29 esophageal cancer samples. We detected Aurora-A expression in 7 esophageal cancer cell lines and 38 esophageal cancers samples by semi-quantitative reverse transcription-PCR and Western blot hybridization. The amplification of Aurora-A was detected in 27 of 29 (93.1%) esophageal cancer samples and 6 of 7 (85.7%) cancer cell lines. Aurora-A was overexpressed in 27 of 38 (71.1%) esophageal cancer samples and all 7 esophageal cancer cell lines. We conclude that Aurora-A is amplified and overexpressed in esophageal squamous cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390048

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  23 in total

1.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

2.  Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Authors:  Laura W Goff; Nilofer S Azad; Stacey Stein; Jennifer G Whisenant; Tatsuki Koyama; Ulka Vaishampayan; Howard Hochster; Roisin Connolly; Amy Weise; Patricia M LoRusso; Safia N Salaria; Wael El-Rifai; Jordan D Berlin
Journal:  Invest New Drugs       Date:  2018-09-06       Impact factor: 3.850

3.  Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.

Authors:  Sujatha Venkataraman; Irina Alimova; Tiffany Tello; Peter S Harris; Jeffrey A Knipstein; Andrew M Donson; Nicholas K Foreman; Arthur K Liu; Rajeev Vibhakar
Journal:  J Neurooncol       Date:  2012-01-15       Impact factor: 4.130

4.  Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway.

Authors:  Ilana Chefetz; Jennie C Holmberg; Ayesha B Alvero; Irene Visintin; Gil Mor
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

5.  Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.

Authors:  Karthik Venkatakrishnan; Tae Min Kim; Chia-Chi Lin; Lim Soon Thye; Wee Joo Chng; Brigette Ma; Ming Huang Chen; Xiaofei Zhou; Hua Liu; Virginia Kelly; Won Seog Kim
Journal:  Invest New Drugs       Date:  2015-06-19       Impact factor: 3.850

6.  Aurora-A modulates MMP-2 expression via AKT/NF-κB pathway in esophageal squamous cell carcinoma cells.

Authors:  Xiaoxia Wang; Xiaozhong Li; Chaohui Li; Chun He; Benhong Ren; Qing Deng; Wei Gao; Binquan Wang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-04-28       Impact factor: 3.848

7.  AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway.

Authors:  Jichang Wu; Liyun Yang; Yamin Shan; Changping Cai; Shili Wang; Hao Zhang
Journal:  Oncol Lett       Date:  2016-01-14       Impact factor: 2.967

8.  Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.

Authors:  Gerald Falchook; Razelle Kurzrock; Launce Gouw; David Hong; Kimberly A McGregor; Xiaofei Zhou; Hongliang Shi; Howard Fingert; Sunil Sharma
Journal:  Invest New Drugs       Date:  2014-06-01       Impact factor: 3.850

9.  Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma.

Authors:  Xiaoying Shang; Susan M Burlingame; M Fatih Okcu; Ningling Ge; Heidi V Russell; Rachel A Egler; Rodney D David; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

10.  Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.

Authors:  Lihong Wang-Bishop; Zheng Chen; Ahmed Gomaa; Albert Craig Lockhart; Safia Salaria; Jialiang Wang; Keeli B Lewis; Jeffrey Ecsedy; Kay Washington; Robert Daniel Beauchamp; Wael El-Rifai
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.